Liver cancer drug combo vs. local therapy: trial ends early

NCT ID NCT05537402

Terminated Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to compare two standard treatments for people with large intermediate-stage liver cancer that cannot be surgically removed. One group would receive a combination of two immunotherapy drugs (atezolizumab and bevacizumab), while the other would receive local treatments like chemoembolization or radioembolization. The trial was terminated after enrolling only one participant, so no meaningful results were obtained.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and bevacizumab (immunotherapy drugs)
What this could lead to: If successful, this could show that a drug combination works better than local treatments for certain liver cancer patients.
What could go wrong: The trial was terminated after enrolling only 1 person, so results are not available. It is too early to draw any conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.